LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

But camizestrant’s use could depend on uptake of monitoring – for now.

The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.